Brokerages expect that Albireo Pharma Inc (NASDAQ:ALBO) will announce ($0.97) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Albireo Pharma’s earnings. The highest EPS estimate is ($0.68) and the lowest is ($1.08). Albireo Pharma posted earnings per share of ($0.73) in the same quarter last year, which would indicate a negative year over year growth rate of 32.9%. The company is expected to report its next earnings report on Tuesday, November 13th.
On average, analysts expect that Albireo Pharma will report full year earnings of ($3.39) per share for the current fiscal year, with EPS estimates ranging from ($3.70) to ($2.75). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.95) per share, with EPS estimates ranging from ($6.06) to ($2.13). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Albireo Pharma.
Albireo Pharma (NASDAQ:ALBO) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.24). The business had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $2.00 million.
In other news, insider Ronald Harold Wilfred Cooper purchased 788 shares of Albireo Pharma stock in a transaction on Tuesday, August 14th. The shares were purchased at an average cost of $31.85 per share, for a total transaction of $25,097.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 3.60% of the stock is owned by insiders.
Several hedge funds have recently made changes to their positions in the company. Federated Investors Inc. PA lifted its position in shares of Albireo Pharma by 89.1% during the second quarter. Federated Investors Inc. PA now owns 586,146 shares of the biopharmaceutical company’s stock worth $20,808,000 after purchasing an additional 276,221 shares in the last quarter. BlackRock Inc. lifted its position in shares of Albireo Pharma by 582.8% during the second quarter. BlackRock Inc. now owns 524,276 shares of the biopharmaceutical company’s stock worth $18,611,000 after purchasing an additional 447,496 shares in the last quarter. Chicago Capital LLC lifted its position in shares of Albireo Pharma by 18.9% during the third quarter. Chicago Capital LLC now owns 160,248 shares of the biopharmaceutical company’s stock worth $5,282,000 after purchasing an additional 25,500 shares in the last quarter. Millennium Management LLC lifted its position in shares of Albireo Pharma by 234.0% during the first quarter. Millennium Management LLC now owns 155,611 shares of the biopharmaceutical company’s stock worth $5,068,000 after purchasing an additional 109,017 shares in the last quarter. Finally, Heartland Advisors Inc. lifted its position in shares of Albireo Pharma by 36.9% during the second quarter. Heartland Advisors Inc. now owns 125,000 shares of the biopharmaceutical company’s stock worth $4,438,000 after purchasing an additional 33,677 shares in the last quarter. Institutional investors own 63.44% of the company’s stock.
NASDAQ:ALBO traded down $0.47 on Friday, reaching $27.38. The stock had a trading volume of 734 shares, compared to its average volume of 33,243. The firm has a market cap of $347.37 million, a PE ratio of -8.64 and a beta of 1.74. Albireo Pharma has a 1-year low of $21.25 and a 1-year high of $39.87.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Further Reading: What is the yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.